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OBJECTIVE — To assess the relationship between annual ﬁlls for antidiabetes medications,
ACE inhibitors, angiotensin II receptor blockers (ARBs), and lipid-lowering agents on hospital-
ization and Medicare spending for beneﬁciaries with diabetes.
RESEARCH DESIGN AND METHODS — Using Medicare Current Beneﬁciary Survey
data from 1997 to 2004, we identiﬁed 7,441 community-dwelling beneﬁciaries with diabetes,
who contributed 14,317 person-years of data for the analysis. We used multivariate regression
analysis to estimate the effect of persistency in medication ﬁlls on hospitalization risk, hospital
days, and Medicare spending.
RESULTS — For users of older oral antidiabetes agents, ACE inhibitors, ARBs, and statins,
each additional prescription ﬁll was associated with signiﬁcantly lower risk of hospitalization,
fewer hospital days, and lower Medicare spending.
CONCLUSIONS — These results suggest an economic case for promoting greater persis-
tency in use of drugs with approved indications by Medicare beneﬁciaries with diabetes; how-
ever, additional research is needed to corroborate the study’s cross-sectional ﬁndings.
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A
pproximately 25% of Medicare
beneﬁciaries have diabetes (1). In
2002, the average beneﬁciary with
diabetes spent $15,292 on medical ser-
vices including $2,349 for prescription
medications (1). The economic burden of
diabetes is huge—$27 billion in 2007 (2)
rising to possibly $190 billion by 2020
(3).
Recent studies suggest that better
medication management for older indi-
viduals with diabetes not only improves
health (4) and reduces mortality (5), but
also has the potential to reduce future
medical care costs (6) and may be cost
saving to the Medicare program (4–5,
7–9).
In this article, we examine annual
prescription ﬁll rates for antidiabetes
medications, ACE inhibitors, angiotensin
II receptor blockers (ARBs), and lipid-
lowering agents among Medicare beneﬁ-
ciaries with diabetes between 1997 and
2004. We then test to determine whether
increased utilization is associated with
lower hospitalization rates and savings in
traditional Medicare services.
RESEARCH DESIGN AND
METHODS— The study uses Medi-
care Current Beneﬁciary Survey (MCBS)
data. Cases were selected based on self-
reported diabetes or the presence of an
ICD-9 code for diabetes and complica-
tions (250.xx), polyneuropathy in diabe-
tes (357.2), diabetic retinopathy (362.01,
362.02), or diabetic cataract (366.41) on
one hospital, skilled nursing facility, or
home health claim or any of these codes
ontwooutpatientorphysicianclaimsfol-
lowing a validated protocol (10,11).
These selection criteria resulted in a sam-
ple of 7,441 individuals with diabetes
who contributed 14,317 annual observa-
tions for the analysis.
We used MCBS prescription medica-
tion ﬁles to identify users of the following
sevendrugclasses:olderoralantidiabetes
drugs (metformin and sulfonylureas),
newer oral agents (thiazolidinediones,
meglitinides, and -glucosidase inhibi-
tors), insulins, ACE inhibitors, ARBs,
statins, and other lipid-lowering medica-
tions(ezetimibe,ﬁbrates,niacin,andoth-
ers). The primary explanatory variable in
our analysis is the annual number of pre-
scription ﬁlls per class per year.
We assessed the effect of prescrip-
tion ﬁll rates for users of each drug class
on the risk of hospitalization, total an-
nual hospital days, and spending on
Medicare services measured in constant
2006 dollars, using the Consumer Price
Index (12). Covariates included an ex-
tensive list of demographic, socioeco-
nomic, and health status indicators (see
Table A1 in the online appendix avail-
able at http://care.diabetesjournals.org/
cgi/content/full/dc08-1311/DC1).
We estimated seven regression mod-
els, one per drug class, for each of the
three dependent variables using person-
year as the unit of analysis and the full set
of covariates listed in the online appen-
dix.Becausethestudysubjectsfrequently
used medications in two or more drug
classes, we included ﬁll rates for all seven
drugclassesineachequation.Thisproce-
dure assured that the parameter coefﬁ-
cient on prescription ﬁlls for the subset of
users of a particular drug class was condi-
tioned on utilization of the other medica-
tion classes.
We used logistic regression for the
hospitalization models and Poisson re-
gression for the hospital day equations.
For the Medicare spending models, we
used a generalized linear equation with a
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the skewed distribution of Medicare ex-
penditures (13). All models were esti-
mated in Stata (Release 9) with a robust
cluster command to correct standard er-
rors for repeated measures among sub-
jects observed in multiple years. Results
are reported as conditional marginal
probabilities (hospitalization) or condi-
tional marginal effects (dy/dx) of a unit
change in prescription ﬁlls on the change
in the dependent variable (hospital days
and Medicare spending), with all other
variables held at their mean values.
RESULTS— Almost one-third (30%)
of the sample was hospitalized each year
withratesrangingfrom27.4%forusersof
older antidiabetes medications to 42.9%
for insulin users (Table 1). The mean
number of inpatient days varied in a sim-
ilar fashion. Mean annual Medicare
spending ranged between 8,565 USD
(older oral antidiabetes medication users)
and 16,950 USD (insulin users).
User rates varied widely across the
seven drug classes. Annual prevalence of
older oral antidiabetes drug use was
47.1% compared with 13.3% for newer
agents. Insulin use was infrequent
(6.1%). The highest average annual ﬁll
rate was for older oral antidiabetes drugs
(8.3), with annual ﬁlls hovering around 6
for the other classes.
The regression results are summa-
rized in Table 1. Overall, we found a con-
sistent inverse relationship between
prescriptionﬁllratesandthethreedepen-
dent variables for older oral antidiabetes
agents, ACE inhibitors, ARBs, and statins.
The marginal effects of prescription ﬁlls
for these four classes were negative and
statistically signiﬁcant in every case. Each
additional prescription ﬁll by users of
older oral antidiabetes agents reduced
hospitalization risk by 0.3%, reduced the
number of hospital days by 0.04 days,
and reduced Medicare spending by $71.
Each added ﬁll for ARB users reduced
hospitalization risk by 1.3%, reduced the
number of hospital days by 0.12 days,
and reduced Medicare spending by $159.
Similarresultswereseenfortheothertwo
drug classes.
The hospital effects may appear to be
small, but with an average Medicare cost
of $952 per inpatient day in 2006 (14),
the results translate into hospital cost off-
setsrangingfrom$38perprescriptionfor
older oral antidiabetes agents to $114 for
ARBs. For three of the drug classes, esti-
matedMedicaresavingsexceededthecost
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The average unit cost of an older oral an-
tidiabetes agent was $49 (in constant
2006dollars)forourstudysampleor$22
less than the estimated saving associated
with an additional ﬁll. For ACE inhibitors
and ARBs, the estimated unit costs were
$58 and $71, signiﬁcantly lower than the
estimated Medicare savings per ﬁll of
$154 and $159, respectively.
CONCLUSIONS — We ﬁnd consis-
tent evidence that more persistent use of
older oral antidiabetes drugs, ACE inhib-
itors, ARBs, and statins is associated with
reducedhospitalizationandlowerspend-
ing for traditional Medicare services by
beneﬁciaries with diabetes. These ﬁnd-
ingsareconsistentwithpreviousresearch
showing that underuse of these agents is
associatedwithgreaterriskofhospitaliza-
tion and higher medical costs for individ-
uals with diabetes (5,7–9,15). The study
results suggest a case for promoting
greater use of drugs with approved indi-
cations by Medicare beneﬁciaries with di-
abetes; however, additional research is
needed to corroborate the study’s cross-
sectional ﬁndings.
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